Tác động lâu dài của lovastatin đơn độc và kết hợp với cholestyramine đến mức lipoprotein (a) ở bệnh nhân có tiền sử gia đình tăng cholesterol máu

Albers AW, Chen J, Kuron G, Hunt V, Huff V, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J (1980) Mevinolin — a highly potent competitive inhibitor of hydroxymethylglutarylcoenzyme A reductase and a cholesterol lowering agent. Proc Natl Acad Sci USA 77:3957–3961 Armstrong VM, Walli, AK Seidel J (1985) Isolation, characterization and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained by reduction of lipoprotein(a). J Lipid Res 26:1314–1323 Berg K (1963) A new serum type system in man — the Lp system. Acta Pathol Microbiol Scand 59:369–382 Berg K (1979) Inherited lipoprotein variation and atherosclerotic disease. In: Scanu AM, Wissler RW, Getz GS (eds) The biochemistry of atherosclerosis. Dekker, New York, pp 419–489 Berg K, Dahlen G, Frick MH (1974) Lp(a) lipoprotein and pre-ß-lipoprotein in patients with coronary heart disease. Clin Genet 6:230–235 Bilheimer DW, Grundy SM, Brown MS, Goldstein JL (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80:4124–4128 Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232:34–37 Brown MS, Goldstein JL (1991) The hyperlipoproteinemias and other disorders of lipid metabolism. In: Wilson JD, Braunwald E, Issellacher KI, Petersdorf RG, Martin JB, Fauci AS, Root RK (eds) Harrison's principles of internal medicine, 11th edn. McGraw-Hill, New York, p 1650 Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med 226:271–276 Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu Q-T, Miller CG, Lawn RM, Scanu AM (1987) Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 84:3224–3228 Fless GM, Rolih CA, Scanu AM (1984) Heterogeneity of human plasma lipoprotein (a). J Biol Chem 258:11470–11478 Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18:499–502 Gaubatz JW, Heideman C, Gotto AM Jr, Morrisset JD, Dahlen G (1983) Human plasma lipoprotein (a). J Biol Chem 258:4582–4589 Havekes L, Vermeer BJ, Brugman T, Emeis J (1981) Binding of Lp(a) to the low density lipoprotein receptor of human fibroblasts. FEBS Lett 132:169–173 Hjermann I (1980) Smoking and diet intervention in healthy coronary high risk men. Methods and 5-year follow-up of risk factors in a randomized trial. J Oslo City Hosp 30:3–17 Illingworth DR (1988) Drug therapy of hypercholesterolemia. Clin Chem 34:123–132 Jacob BG, Richter WO, Schwandt P (1990) Lovastatin, pravastatin and serum lipoprotein (a). Ann Int Med 112:713–714 Jurgens G, Ashy A, Zenker G (1989) Raised serum lipoprotein during treatment with lovastatin. Lancet I:911–912 Knight BL, Perombelon YFN, Soutar AK, Wade DP, Seed M (1991) Catabolism of lipoprotein (a) in familial hypercholesterolaemic subjects. Atherosclerosis 87:227–237 Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL (1989) HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80:1313–1319 Krempler VWF, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F (1982) Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 71:1431–1441 Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L (1988) Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 73:35–41 Maartmann-Moe K, Berg K (1981) Lp(a) lipoprotein enters cultured fbroblasts independently of the plasma membrane low density lipoprotein receptor. Clin Genet 20:352–362 McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen YE, Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 330:132–137 Morrisset JD, Guyton JR, Gaubatz JW, Gotto AM Jr (1987) Lipoprotein (a); structure, metabolism and epidemiology. In: Gotto AM Jr (ed) Plasma lipoproteins. Elsevier, Amsterdam, pp 129–152 Ojala J-P, Helve E, Karjalainen K, Tarkkanen A, Tikkanen MJ (1990) Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. Atherosclerosis 82:85–95 Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL (1986) Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 256:2540–2544 Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G (1990) Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322:1494–1499 Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG (1980) Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 302:1219–1222 Thiery J, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Seidel D (1988) Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 66:462–463 Utermann G (1989) The mysteries of lipoprotein (a). Science 246:904–910 Utermann G, Weber W (1983) Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 154:357–361 Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (1987) Lp(a) glycoprotein phenotypes. J Clin Invest 80:458–465 Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E (1989) Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 86:4171–4174 Vega GL, Grundy SM (1987) Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. J Am Med Assoc 257:33–38 Vessby B, Kostner G, Lithell H, Thomis J (1982) Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 44:61–71 Wiklund O, Angelin B, Olofsson S-E, Eriksson M, Fager G, Berglund L, Bondjers G (1990) Apolipoprotein (a) and ischaemic heart disease in familial hypercholesterolemia. Lancet 335:1360–1363